Overview

Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

Status:
Recruiting

Trial end date:
2024-04-24

Target enrollment:

Participant gender:

Summary

The study is a Phase II clinical trial. Patients will receive intensity modulated total marrow irradiation (TMI) at a dose of 9 Gy with standard myeloablative fludarabine/ i.v. targeted busulfan (FluBu) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT).

Phase:

Phase 2

Details

Lead Sponsor:

University of Illinois at Chicago

Treatments:

Busulfan
Fludarabine
Fludarabine phosphate
Methotrexate
Tacrolimus
Thymoglobulin
Vidarabine